Anti-Infective Agents Market Size, Share, Growth and Forecast (2026 - 2036)

Anti-Infective Agents Market Analysis and Forecast by Fact.MR

• The Anti-Infective Agents Market is expected to grow from USD 154.9 billion in 2026 to USD 200.3 billion by 2036, at a 2.6% CAGR.
• Driven by rising antimicrobial resistance and the need for next-generation therapies. Growth is supported by a higher infectious disease burden in aging and immunocompromised populations. Antibacterial agents account for 48.3% of product demand while respiratory infection treatment contributes 39.7% share. Companies are investing in resistance-aware drug design and accelerated regulatory pathways for priority pathogens.
• 48.3% share of the product segment and respiratory infection treatment contributing 39.7% share as companies invest in resistance-aware drug design, stewardship-compatible commercial models, and accelerated regulatory pathways for priority pathogens.

Summary of Anti-Infective Agents Market

• Market Snapshot
  • In 2025, the global Anti-Infective Agents Market was valued at approximately USD 151.0 billion.
  • The market is estimated to reach USD 154.9 billion in 2026 and is projected to attain USD 200.3 billion by 2036.
  • The anti-infective agents market is likely to expand at a CAGR of 2.6% during the forecast period.
  • The market is anticipated to create an absolute dollar opportunity of USD 45.4 billion between 2026 and 2036.
  • Antibacterial agents account for 48.3% of product segment share in 2026.
  • China (7.4%) and U.S. (6.8%) are the key growth markets during the forecast period.
• Demand and Growth Drivers
  • The rising prevalence of antimicrobial resistance among gram-negative and gram-positive pathogens has resulted in an urgent need for new antibiotic and antifungal treatment options.
  • The patient populations that require anti-infective therapy are increasing due to the aging population and the greater number of immunocompromised patients due to cancer therapy and organ transplantation.
  • Regulatory incentives that stimulate investments in the development of anti-infective drugs include extensions to the GAIN Act and proposals for the PASTEUR Act and EMA priority review pathways.
  • Targeted, narrow-spectrum anti-infective agents are being adopted as a result of hospital-acquired infection control programs and antimicrobial stewardship mandates.
  • The volume growth is supported by the growth in access to anti-infective therapies in the emerging markets, driven by generic drug manufacturing and international procurement programs.
• Product and Segment View
  • Antibacterial agents will hold the largest product share of 48.3% in 2026, due to the dominant treatment need in respiratory, urinary, skin and hospital-acquired bacterial infections.
  • 36.4% of the mechanism of action share is attributed to cell wall inhibition systems, highlighting the established role of beta-lactam and glycopeptide antibiotics in clinical practice.
  • Key segmentation includes:
    • Product: Antibacterial Agents, Antiviral Agents, Antifungal Agents, Antiparasitic Agents
    • Route of Administration: Oral Anti-Infective Agents, Injectable Anti-Infective Agents, Topical Anti-Infective Agents
    • Application: Respiratory Infection Treatment, Urinary Tract Infection Treatment, Skin Infection Treatment, Hospital-Acquired Infection Treatment
  • These therapies address:
    • Bacterial, viral, fungal, and parasitic infections across community and hospital settings
    • Drug-resistant pathogen infections requiring targeted, mechanism-specific treatment approaches
    • Prophylactic and therapeutic needs in immunocompromised patient populations
• Geography and Competitive Outlook
  • Asia Pacific leads growth, with China at 7.4% CAGR driven by hospital expansion, centralized drug procurement reforms, and domestic generic manufacturing capacity.
  • North America at 6.8% (U.S.) reflects FDA regulatory pathway support, specialty pharmacy distribution, and strong clinical adoption of next-generation anti-infectives.
  • Europe shows steady growth, with Germany at 6.0% and UK at 5.9% supported by EU MDR compliance, NHS procurement frameworks, and NICE health technology assessments.
  • Major players include GlaxoSmithKline plc., Pfizer Inc., Bayer AG, Sanofi, Merck and Co. Inc., Bristol-Myers Squibb Company, Abbott, Novartis AG, Johnson and Johnson Services Inc., Gilead Sciences Inc., and Astellas Pharma Inc.
• Analyst Opinion
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, says "The anti-infective agents market is entering a structural inflection point where antimicrobial resistance is forcing a fundamental rethink of drug development economics and commercial models. The approval of first-in-class antibiotics like gepotidacin and zoliflodacin in 2025 signals that the pipeline is producing clinically relevant molecules, but the commercial challenge remains: stewardship requirements limit prescribing volumes for new antibiotics precisely when they are most needed as reserve therapies. Companies that can navigate this tension between clinical need and commercial viability through subscription-based procurement and delinked revenue models are positioned to capture long-term value."

Key Growth Drivers, Constraints, and Opportunities

Key Factors Driving Growth

• The urgent need for new classes of treatment is being driven by antimicrobial resistance in WHO priority pathogens such as carbapenem-resistant Enterobacteriaceae and drug-resistant gonorrhea.
• Regulatory incentive programs such as transferable exclusivity vouchers and subscription-based procurement pilots are helping to make new antibiotic development commercially viable.
• The ongoing demand for treatment is driven by a growing infectious disease burden, aging demographics, rising immunocompromised populations and post-pandemic healthcare system strengthening.

Key Market Constraints

• Antimicrobial stewardship programs deliberately limit the prescription of new antibiotics in order to preserve their efficacy and this creates a tension between clinical conservation and commercial revenue generation.
• The entry of generics quickly after patent expiry constrains the commercial life cycle of branded anti-infective products through margin compression.
• The high failure rate of clinical trials and long development time for anti-infective drug candidates means that pharmaceutical companies face substantial R&D investment risk.

Key Opportunity Areas

• The subscription-based and delinked procurement models being piloted in the UK, Sweden and the U.S. offer a pathway to sustainable commercial returns for reserve-class antibiotics.
• Antifungal drug development is attracting renewed investment with several novel agents advancing through clinical trials and invasive fungal infections are on the rise in immunocompromised populations.
• The oral formulations of anti-infective agents that were previously limited to injection increase the scope of treatment from the hospital to the outpatient and community care setting.

Segment-wise Analysis of the Anti-Infective Agents Market

• Antibacterial agents will hold 48.3% share of product in 2026 indicating the overwhelming treatment need across respiratory, urinary, skin and hospital acquired bacterial infections.
• Oral anti-infective agents account for the largest share in the route of administration segment at 44.1% owing to the advantages of patient compliance and outpatient prescription trends.
• The respiratory infection treatment segment is anticipated to contribute 39.7% of application share in 2026, with community-acquired pneumonia and bronchitis as the primary volume drivers.

The market is segmented by product, route of administration, mechanism of action, application, drug class and region. Antibacterial agents dominate treatment volume and clinical need with antiviral agents the fastest growing category driven by the need for hepatitis, HIV and respiratory viral infection treatment. Broad spectrum agents represent 42.8% of the drug class share.

Which Product Segment Dominates the Anti-Infective Agents Market?

Antimicrobial agents constitute 48.3% of 2026 product segment value. Their leadership reflects the spectrum and incidence of bacterial infections that require pharmacological treatment, ranging from community-acquired respiratory and urinary tract infections to hospital-acquired and surgical site infections. Beta-lactams, fluoroquinolones and macrolides remain the mainstay of antibacterial prescribing.

The second largest segment is the use of antiviral agents, which is propelled by continued treatment needs for HIV, hepatitis B and C, and respiratory viral infections. Antifungals are smaller by market share but growing faster, propelled by increasing rates of invasive fungal infections in the immunocompromised patient population.

Which Application Segment Dominates the Anti-Infective Agents Market?

39.7% lead application share in 2026 for treatment of respiratory infection. The greatest numbers of prescriptions for anti-infective agents worldwide are for community-acquired pneumonia, acute bronchitis and upper respiratory tract infections. This segment benefits from a large patient population in all age groups and geographic regions.

The next biggest use is for treatment of urinary tract infections. New oral antibiotics such as gepotidacin, recently approved for use, are opening up more choices for doctors. Treatment of hospital-acquired infections is a higher per-patient value segment where premium-priced resistance targeted agents generate outsized revenue relative to treatment volume.

Which Product Trend is Shaping the Next Phase of Growth in the Anti-Infective Agents Market?

First-in-class antibiotics, with novel mechanisms of action, are revolutionizing the anti-infective pipeline after years of stagnation. Gepotidacin, a triazaacenaphthylene topoisomerase inhibitor, and zoliflodacin, a spiropyrimidinetrione type II topoisomerase inhibitor, are the first, truly novel antibiotic classes to reach patients in decades with their approvals in 2025. Both drugs are taken orally and target drug-resistant pathogens, widening their availability to settings other than hospitals.

This pipeline renewal is backed by public private partnerships such as GARDP, BARDA and CARB-X that share in the development risk and costs with pharmaceutical companies. The commercial models for these products are changing from traditional volume-based sales to subscription and pull incentive models that provide rewards for antibiotic availability rather than prescribing volume, thus supporting antimicrobial stewardship objectives.

Regional Outlook Across Key Markets

• China leads at 7.4%, driven by hospital expansion, centralized drug procurement (VBP) reforms, and domestic generic anti-infective manufacturing capacity.
• The U.S. at 6.8% reflects strong FDA regulatory support for anti-infective development, specialty pharmacy networks, and clinical adoption of new resistance-targeted agents.
• European markets show moderate growth, with Germany at 6.0% supported by EU MDR compliance and GKV reimbursement, and UK at 5.9% driven by NHS procurement and subscription-based antibiotic models.

CAGR Table

Source: Fact.MR analysis, based on proprietary forecasting model and primary research.

Market Outlook for Anti-Infective Agents in China

The China Anti-Infective Agents Market is expected to grow at a CAGR of 7.4% through 2036 The volume-based purchasing program is changing the way anti-infective agents are acquired and distributed throughout the hospital system and domestic generics manufacturers are increasing production capacity to meet domestic and export demand.

• Hospital expansion in tier-2 and tier-3 cities is widening the institutional base for prescribing anti-infective agents.
• Domestic pharmaceutical innovation and expansion of anti-infective manufacturing capacity are strengthening China's position in antibacterial and antiviral therapeutics.
• VBP procurement cycles are compressing generic antibiotic pricing while expanding volume access across the hospital system.

U.S. Anti-Infective Agents Demand Trends

The U.S. Anti-Infective Agents Market is expected to grow at a CAGR of 6.8% over the forecast period (2023-2036). FDA regulatory pathways such as qualified infectious disease product designation and GAIN Act provisions support investment in anti-infective drug development, while specialty pharmacy networks and hospital formulary committees shape clinical adoption patterns.

• The economics of anti-infective prescribing are affected by insurance and reimbursement frameworks, such as Medicare Part D and specialty pharmacy benefit designs.
• Hospital system consolidation concentrates anti-infective procurement power and influences formulary standardization across health networks.
• Subscription-based procurement pilots for reserve antibiotics are being tested to sustain commercial viability of resistance-targeted products.

Germany Anti-Infective Agents Market Growth Assessment

The Germany Anti-Infective Agents Market is projected to grow at a CAGR of 6.0% through 2036. Germany's antimicrobial stewardship programs, hospital infectious disease management protocols, and demand for resistance-targeted therapies are supporting market growth.

• GKV system Reference pricing mechanisms affect the uptake of generic anti-infectives and the pricing caps for branded products.
• Antimicrobial stewardship programs and hospital consolidation are leading to the concentration of power to prescribe reserve-class antibiotics.
• EMA processes harmonize regulations across the EU, providing a single market access route for anti-infective drug approval.

UK Anti-Infective Agents Market Growth Outlook

UK Anti-Infective Agents Market is anticipated to grow at a CAGR of 5.9% till 2036. Impact of NICE health technology assessments and NHS procurement frameworks on clinical uptake and pricing of anti-infectives. The UK's subscription-based antibiotic procurement model is closely watched as a global pilot for delinked revenue approaches.

• NHS procurement frameworks are testing subscription-based contracts that pay for antibiotic availability rather than volume prescribed.
• Post-Brexit regulatory divergence from the EMA means that anti-infective products in the UK market have different approval timelines.
• Evidence-based prescribing guidelines and formulary decisions are supported by antimicrobial resistance surveillance programs.

Japan Anti-Infective Agents Market Demand Analysis

The Japan Anti-Infective Agents Market is projected to expand at a CAGR of 5.7% by 2036. PMDA approval pathways, NHI pricing revision affect pharmaceutical companies’ launch strategies for anti-infective products. The aging population remains a source of ongoing demand for treatment of respiratory and urinary tract infections.

• NHI pricing revisions apply biennial downward adjustments that compress anti-infective drug margins over product lifecycles.
• The market access timelines for imported anti-infective products are dictated by domestic supplier preference and long qualification cycles.
• An aging population continues to provide prescribing demand for respiratory and urinary tract infection treatments.

Competitive Benchmarking and Company Positioning

Anti-Infective Agents Market Analysis By Company

• GlaxoSmithKline continues to lead with an estimated 21.0% market share due to its broad anti-infective portfolio spanning antibacterial, antiviral and vaccine adjacent therapeutic areas, supported by the 2025 approval of gepotidacin (Blujepa).
• Pfizer, Merck and Co. and Johnson and Johnson are diversified pharmaceutical companies with global distribution infrastructure and established formulary positions in major hospital anti-infective categories.
• Gilead Sciences and Bristol-Myers Squibb have also a strong presence in the antiviral segments, especially in HIV and hepatitis treatment segments, with their concentrated therapeutic area expertise and long-term patient management programs.

The competitive landscape reflects a bifurcation between large pharmaceutical companies with diversified anti-infective portfolios and smaller, focused companies developing resistance-targeted agents. GSK strengthened its antibacterial position through the dual approval of Blujepa for UTIs and gonorrhea in 2025, while Innoviva/GARDP introduced zoliflodacin for drug-resistant gonorrhea.

Generic competition is intense across established antibiotic and antiviral classes, with branded companies defending market share through reformulation, combination products, and clinical differentiation. The commercial viability challenge for new antibiotics is driving industry interest in subscription-based procurement and pull incentive models.

Key Companies in the Anti-Infective Agents Market

• GlaxoSmithKline plc., Pfizer Inc., Bayer AG, Sanofi, Merck and Co. Inc., Bristol-Myers Squibb Company, Abbott, Novartis AG, Johnson and Johnson Services Inc., Gilead Sciences Inc., and Astellas Pharma Inc. are the leading companies.

Recent Industry Developments

FDA approves Basilea’s antibiotic Zevtera (ceftobiprole) (2024)

• The U.S. FDA approved Basilea Pharmaceutica’s antibiotic Zevtera (ceftobiprole) for serious bacterial infections including multidrug-resistant pathogens such as Staphylococcus aureus bloodstream infections.

FDA approves Iterum Therapeutics oral antibiotic for UTIs (2024)

• The FDA approved Orlynvah, an oral antibiotic for uncomplicated urinary tract infections in adult women with limited treatment options, following successful late-stage trials after a prior rejection.

Wockhardt receives FDA approval for ZAYNICH antibiotic (2026)

• Indian pharma company Wockhardt received FDA approval for ZAYNICH, a novel antibiotic for complicated urinary tract infections, strengthening India’s presence in new chemical entity antibiotics.

Leading Companies Shaping the Anti-Infective Agents Market

• GlaxoSmithKline plc.
• Pfizer Inc.
• Bayer AG
• Sanofi
• Merck and Co., Inc.
• Bristol-Myers Squibb Company
• Abbott
• Novartis AG
• Johnson and Johnson Services Inc.
• Gilead Sciences, Inc.
• Astellas Pharma Inc.

Sources and Research References

• Basilea Pharmaceutica Ltd. (2024, April 4). Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications. Basilea. 
• U.S. Food and Drug Administration. (2025, March 25). FDA approves new treatment for uncomplicated urinary tract infections in adult women who have limited or no alternative oral antibacterial treatment options. U.S. Department of Health and Human Services. 
• Chemxpert. (2026). Wockhardt's Zaynich receives FDA approval for complicated urinary tract infections. Chemxpert. 

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

Key Questions This Report Addresses

• What is the estimated size of the global Anti-Infective Agents Market in 2026, and how is it projected to grow through the 2026 to 2036 forecast period?
• What incremental revenue opportunity is the Anti-Infective Agents Market expected to create between 2026 and 2036, and what CAGR underpins this projection?
• Which product segment holds the largest share in 2026, and what clinical demand patterns support antibacterial agent leadership?
• How is the balance between branded and generic anti-infective agents expected to shift over the forecast period across major therapeutic classes?
• Which application segment is projected to generate the most incremental revenue through 2036, and what drives respiratory infection treatment demand?
• Which countries are projected to register the highest CAGR through 2036, and what healthcare system factors accelerate their growth?
• How do demand patterns in China compare with those in the U.S. and Europe in terms of procurement models, pricing structures, and prescribing dynamics?
• What regulatory incentives and procurement reforms are most likely to sustain commercial investment in new antibiotic development during the forecast period?
• What supply-side constraints, including R&D failure rates and antimicrobial stewardship restrictions, could limit growth in the new antibiotic segment?
• Who are the leading companies, and how are they differentiating through pipeline depth, clinical specialization, and resistance-targeted drug development?
• What recent regulatory approvals in 2025 are reshaping competitive positioning in the antibacterial and antifungal segments?
• Which drug development or commercial model trend is driving the next phase of growth, and how is it changing pharmaceutical company investment strategies?
• How are subscription-based and delinked procurement models performing in early pilot programs, and what implications do they hold for market structure?
• What role are public-private partnerships like GARDP and BARDA playing in reshaping the anti-infective drug development landscape?

Anti-Infective Agents Market Definition

Anti-infective agents market is segmented by type of treatment into anti-bacterial, anti-viral, anti-fungal and anti-parasitic. It includes antibacterial, antiviral, antifungal and antiparasitic drug classes by oral, injectable and topical routes.

Anti-Infective Agents Market Inclusions

• Global and regional market size and forecasts for 2026 to 2036 across product, route of administration, mechanism of action, application, drug class, and region.
• Demand analysis based on incidence of infectious disease, antimicrobial resistance trends, regulatory incentive programs and hospital stewardship mandates.
• Competitive landscape including drug pipeline analysis, commercial strategies and distribution approaches of major pharmaceutical companies.

Anti-Infective Agents Market Exclusions

• Vaccines, immunoglobulins, and passive immunization products not classified as anti-infective drug therapies.
• Diagnostics, rapid testing, and antimicrobial susceptibility testing products and services.
• Disinfectants, antiseptics, and non-pharmaceutical infection prevention products.

Anti-Infective Agents Market Research Methodology

• Methodology combines secondary research from clinical trial databases, regulatory filings, and pharmaceutical industry publications with primary validation.
• Draws on 120+ secondary sources and benchmarks 50+ company drug portfolios and pipeline assets.
• Market sizing covers 30+ countries with inputs including infectious disease incidence, antimicrobial resistance rates, hospital bed capacity, and drug procurement volumes.
• Primary validation includes over 25 interviews with pharmaceutical companies, hospital infectious disease experts, pharmacy chains and procurement agencies.